116 related articles for article (PubMed ID: 15383460)
1. Mapping of genes that control the antibody response to human factor IX in mice.
Lozier JN; Tayebi N; Zhang P
Blood; 2005 Feb; 105(3):1029-35. PubMed ID: 15383460
[TBL] [Abstract][Full Text] [Related]
2. Stabilization of transgene expression by incorporation of E3 region genes into an adenoviral factor IX vector and by transient anti-CD4 treatment of the host.
Poller W; Schneider-Rasp S; Liebert U; Merklein F; Thalheimer P; Haack A; Schwaab R; Schmitt C; Brackmann HH
Gene Ther; 1996 Jun; 3(6):521-30. PubMed ID: 8789802
[TBL] [Abstract][Full Text] [Related]
3. Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Kung SH; Hagstrom JN; Cass D; Tai SJ; Lin HF; Stafford DW; High KA
Blood; 1998 Feb; 91(3):784-90. PubMed ID: 9446637
[TBL] [Abstract][Full Text] [Related]
4. Muscle as a target for supplementary factor IX gene transfer.
Hoffman BE; Dobrzynski E; Wang L; Hirao L; Mingozzi F; Cao O; Herzog RW
Hum Gene Ther; 2007 Jul; 18(7):603-13. PubMed ID: 17594244
[TBL] [Abstract][Full Text] [Related]
5. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX.
Fields PA; Kowalczyk DW; Arruda VR; Armstrong E; McCleland ML; Hagstrom JN; Pasi KJ; Ertl HC; Herzog RW; High KA
Mol Ther; 2000 Mar; 1(3):225-35. PubMed ID: 10933938
[TBL] [Abstract][Full Text] [Related]
6. Intravenous administration of an E1/E3-deleted adenoviral vector induces tolerance to factor IX in C57BL/6 mice.
Fields PA; Armstrong E; Hagstrom JN; Arruda VR; Murphy ML; Farrell JP; High KA; Herzog RW
Gene Ther; 2001 Mar; 8(5):354-61. PubMed ID: 11313811
[TBL] [Abstract][Full Text] [Related]
7. Genetic analysis of the antibody response to AAV2 and factor IX.
Zhang HG; High KA; Wu Q; Yang P; Schlachterman A; Yu S; Yi N; Hsu HC; Mountz JD
Mol Ther; 2005 Jun; 11(6):866-74. PubMed ID: 15922957
[TBL] [Abstract][Full Text] [Related]
8. Hepatic control elements promote long-term expression of human coagulation factor IX gene in hydrodynamically transfected mice.
Kim HS; Kim JC; Lee YK; Kim JS; Park YS
J Gene Med; 2011 Jul; 13(7-8):365-72. PubMed ID: 21710610
[TBL] [Abstract][Full Text] [Related]
9. Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.
Wang L; Cao O; Swalm B; Dobrzynski E; Mingozzi F; Herzog RW
Gene Ther; 2005 Oct; 12(19):1453-64. PubMed ID: 15889137
[TBL] [Abstract][Full Text] [Related]
10. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.
Herzog RW; Hagstrom JN; Kung SH; Tai SJ; Wilson JM; Fisher KJ; High KA
Proc Natl Acad Sci U S A; 1997 May; 94(11):5804-9. PubMed ID: 9159155
[TBL] [Abstract][Full Text] [Related]
11. Sustained delivery of therapeutic concentrations of human clotting factor IX--a comparison of adenoviral and AAV vectors administered in utero.
Schneider H; Mühle C; Douar AM; Waddington S; Jiang QJ; von der Mark K; Coutelle C; Rascher W
J Gene Med; 2002; 4(1):46-53. PubMed ID: 11828387
[TBL] [Abstract][Full Text] [Related]
12. Immune response after neonatal transfer of a human factor IX-expressing retroviral vector in dogs, cats, and mice.
Xu L; Mei M; Haskins ME; Nichols TC; O'donnell P; Cullen K; Dillow A; Bellinger D; Ponder KP
Thromb Res; 2007; 120(2):269-80. PubMed ID: 17095052
[TBL] [Abstract][Full Text] [Related]
13. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors.
Snyder RO; Miao CH; Patijn GA; Spratt SK; Danos O; Nagy D; Gown AM; Winther B; Meuse L; Cohen LK; Thompson AR; Kay MA
Nat Genet; 1997 Jul; 16(3):270-6. PubMed ID: 9207793
[TBL] [Abstract][Full Text] [Related]
14. Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs.
Zhang J; Xu L; Haskins ME; Parker Ponder K
Blood; 2004 Jan; 103(1):143-51. PubMed ID: 12969967
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic plasma concentrations of human factor IX in mice after gene delivery into the amniotic cavity: a model for the prenatal treatment of haemophilia B.
Schneider H; Adebakin S; Themis M; Cook T; Douar AM; Pavirani A; Coutelle C
J Gene Med; 1999; 1(6):424-32. PubMed ID: 10753068
[TBL] [Abstract][Full Text] [Related]
16. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.
Dai Y; Schwarz EM; Gu D; Zhang WW; Sarvetnick N; Verma IM
Proc Natl Acad Sci U S A; 1995 Feb; 92(5):1401-5. PubMed ID: 7877990
[TBL] [Abstract][Full Text] [Related]
17. Probing the genetic basis for thyrotropin receptor antibodies and hyperthyroidism in immunized CXB recombinant inbred mice.
Aliesky HA; Pichurin PN; Chen CR; Williams RW; Rapoport B; McLachlan SM
Endocrinology; 2006 Jun; 147(6):2789-800. PubMed ID: 16543368
[TBL] [Abstract][Full Text] [Related]
18. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.
Fields PA; Arruda VR; Armstrong E; Chu K; Mingozzi F; Hagstrom JN; Herzog RW; High KA
Mol Ther; 2001 Sep; 4(3):201-10. PubMed ID: 11545610
[TBL] [Abstract][Full Text] [Related]
19. A potential donor gene for the bm1 gene conversion event in the C57BL mouse.
Mellor AL; Weiss EH; Ramachandran K; Flavell RA
Nature; 1983 Dec 22-1984 Jan 4; 306(5945):792-5. PubMed ID: 6656881
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of factor IX gene transfer to skeletal muscle in murine and canine hemophilia B models by adeno-associated viral vector serotype 1.
Arruda VR; Schuettrumpf J; Herzog RW; Nichols TC; Robinson N; Lotfi Y; Mingozzi F; Xiao W; Couto LB; High KA
Blood; 2004 Jan; 103(1):85-92. PubMed ID: 12969984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
